Since the company's clinical data mix-up in a non-small-cell lung cancer study of bavituximab, Peregrine investors have been anxiously waiting to see what, if any, life might remain for the drug in this potentially lucrative indication. Today, the company released interim findings from its investigation into the mishap, and, as one might expect to see from a company with its back against the wall, the findings were considered positive. However, as Brenton Flynn discusses in the following video, investor should approach this with a "once bitten, twice shy" mentality.
If you're an investor looking for huge long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.
RSS Headlines
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the
Report this Comment icon found on every comment.
Report this Comment On January 08, 2013, at 4:46 AM, BSDetector wrote:
So you actually think they are going to lie about the results knowing that 20+ law firms are already on their case Brenton? I don't think so.
I seriously doubt that stupid retailers that live in the dark purchased 62,000,000 shares today. Those were hedge funds buying. This stock will see $3.00+ in no time.
I've been riding this pup since it was 80 cents and intend to stay aboard for a good while longer.
Add your comment.